INDV
Indivior Pharmaceuticals, Inc.
35.80$
-0.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 17.0% | 17.4% | 13.4% | 26.4% | 22.5% | 7.7% | 16.5% | 17.2% | 19.7% | 17.9% | 12.6% | 14.3% | 16.1% | |
| 83.0% | 82.6% | 86.6% | 73.6% | 77.5% | 92.3% | 83.5% | 82.8% | 80.3% | 82.1% | 87.4% | 85.7% | 83.9% | |
| 6.6% | 9.9% | 9.9% | 8.7% | 7.2% | 10.4% | 8.3% | 7.0% | 6.4% | 4.7% | 5.0% | 3.5% | 4.9% | |
| 143.9% | 30.4% | 27.1% | 50.8% | 67.8% | 101.0% | 24.4% | 52.3% | 49.4% | 62.3% | 39.1% | 35.6% | 46.8% | |
| 150.6% | 61.8% | 60.2% | 113.0% | 76.2% | 60.2% | 58.6% | 58.9% | 48.7% | 48.0% | 44.2% | 39.1% | 45.0% | |
| -67.5% | 20.8% | 26.4% | -39.5% | 1.3% | 32.1% | 24.8% | 23.8% | 31.5% | 34.1% | 43.2% | 46.6% | 38.9% | |
| 3.7% | 3.1% | 2.8% | 3.0% | 3.3% | 4.3% | 4.5% | 5.0% | 3.8% | 1.7% | 2.2% | 0.6% | 2.0% | |
| -66.8% | 21.2% | 25.7% | -40.5% | -0.3% | 29.4% | 22.2% | 20.5% | 11.8% | 22.6% | 36.3% | 46.6% | 29.5% | |
| -17.0% | 2.7% | 3.9% | -7.7% | -1.6% | 9.4% | 4.1% | 14.6% | -1.6% | -5.9% | 8.2% | 11.1% | 2.9% | |
| -49.8% | 18.4% | 21.5% | -32.4% | 1.3% | 19.7% | 17.7% | 6.0% | 13.4% | 28.5% | 28.1% | 35.6% | 26.7% | |
| -60.5% | 27.0% | 30.6% | -35.5% | 7.2% | 35.5% | 28.6% | 27.2% | 17.2% | 25.7% | 39.1% | 47.2% | 32.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.